Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-7012 injections and will conduct clinical trials in the near future.

SHR-7012 injection is an innovative drug independently developed by the company to treat cutaneous lupus erythematosus. According to inquiries, there are currently no drugs with the same target approved for marketing at home and abroad. Up to now, the total R&D investment for SHR-7012 injection-related projects is about RMB 25.5 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.